3/24
08:47 am
vivs
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs [Yahoo! Finance]
Medium
Report
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs [Yahoo! Finance]
3/24
08:05 am
vivs
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
Low
Report
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
3/3
08:47 am
vivs
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales [Yahoo! Finance]
Medium
Report
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales [Yahoo! Finance]
3/3
08:05 am
vivs
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
Medium
Report
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
2/11
08:05 am
vivs
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
Low
Report
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
1/29
07:04 pm
vivs
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China [Yahoo! Finance]
High
Report
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China [Yahoo! Finance]
1/29
04:05 pm
vivs
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
High
Report
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
1/23
05:09 am
vivs
VivoSim Labs (NASDAQ:VIVS) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
VivoSim Labs (NASDAQ:VIVS) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
1/6
08:05 am
vivs
VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer
Low
Report
VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer